Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 105 of the 106 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A growing body of evidence has suggested that metformin potentially reduces the risk of cancer. Our objective was to enhance the precision of estimates of the effect of metformin on the risk of any-site and site-specific cancers in patients with diabetes. METHODS/PRINCIPAL FINDINGS: We performed a search of MEDLINE, EMBASE, ISI Web of Science, Cochrane Library, and ClinicalTrials.gov for pertinent articles published as of October 12, 2011, and included them in a systematic review and meta-analysis. We calculated pooled risk ratios (RRs) for overall cancer mortality and cancer incidence. Of the 21,195 diabetic patients reported in 6 studies (4 cohort studies, 2 RCTs), 991 (4.5%) cases of death from cancer were reported. A total of 11,117 (5.3%) cases of incident cancer at any site were reported among 210,892 patients in 10 studies (2 RCTs, 6 cohort studies, 2 case-control studies). The risks of cancer among metformin users were significantly lower than those among non-metformin users: the pooled RRs (95% confidence interval) were 0.66 (0.49-0.88) for cancer mortality, 0.67 (0.53-0.85) for all-cancer incidence, 0.68 (0.53-0.88) for colorectal cancer (n = 6), 0.20 (0.07-0.59) for hepatocellular cancer (n = 4), 0.67 (0.45-0.99) for lung cancer (n = 3). CONCLUSION/SIGNIFICANCE: The use of metformin in diabetic patients was associated with significantly lower risks of cancer mortality and incidence. However, this analysis is mainly based on observational studies and our findings underscore the more need for long-term RCTs to confirm this potential benefit for individuals with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin may also confer a decreased cancer risk in patients with diabetes (90).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“All the procedures were in accordance with the guidelines for the Quality of Reporting of Meta-analyses [24], the meta-analysis of observational studies in epidemiology [25] and the PRISMA statement [26].”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.008 · Cited by 17,893
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630 · cited 1×
“In light of the fact that cancer is the second and diabetes the twelfth leading cause of death worldwide [59] and that the number of people with diabetes is”
BackgroundMoher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Ding, E. L., Song, Y., Malik, V. S., & Liu, S. (2006) · JAMA · doi:10.1001/jama.295.11.1288 · Cited by 1,354
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 2×
“Five studies (3 cohort studies [36,39,40] and 2 case-control”
BackgroundType-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., Barzi, F., & Woodward, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602619 · Cited by 1,105 · cited 1×
“1) [6,7], and also a decreased risk of prostate cancer (0.”
BackgroundGlycemic index, glycemic load, and chronic disease risk—a meta-analysis of observational studies
Barclay, A. W., Petocz, P., McMillan-Price, J., Flood, V. M., Prvan, T., Mitchell, P., & Brand-Miller, J. C. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.3.627 · Cited by 1,061
Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis
Larsson, S. C., Orsini, N., & Wolk, A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji375 · Cited by 1,038
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996 · cited 5×
“Five studies (3 cohort studies [36,39,40] and 2 case-control”
BackgroundInfluentialFasting Serum Glucose Level and Cancer Risk in Korean Men and Women
Jee, S. H. (2005) · JAMA · doi:10.1001/jama.293.2.194 · Cited by 988
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918 · cited 4×
“Compared with recently published studies [18,19], our updated”
BackgroundResultInfluentialLe Roith, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702273360907 · Cited by 897
Barone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881 · cited 1×
“In light of the worldwide diabetes epidemic and the higher mortalities in cancer patients with diabetes [20,21], explorations of effective cancer prevention are of clinical importance for the targeted management of diabetes in daily practice.”
BackgroundJiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 2×
“The fact that one preliminary study suggested a promising effect of metformin on pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer [87] may point to the possibility that metformin simply augmented the efficacy of chemotherapy for breast cancer [18,86].”
BackgroundDiabetes mellitus and risk of breast cancer: A meta‐analysis
Larsson, S. C., Mantzoros, C. S., & Wolk, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22717 · Cited by 875
El–Serag, H. B., Hampel, H., & Javadi, F. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.12.007 · Cited by 826
Giovannucci, E. (1995) · Cancer Causes and Control · doi:10.1007/bf00052777 · Cited by 817
Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis
Everhart, J. (1995) · JAMA · doi:10.1001/jama.273.20.1605 · Cited by 742
Epidemiology of pancreatic cancer: an overview
Raimondi, S., Maisonneuve, P., & Lowenfels, A. B. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.177 · Cited by 740 · cited 1×
“For instance, elevated levels of insulin and glucose may exert an important influence in the development or growth of epithelial malignant tumors of the colon [91–93], pancreas [94,95], and breast [96], and metformin may prevent incident colon cancer in non-diabetic subjects [88].”
BackgroundFrequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0804 · Cited by 631
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Antidiabetic Therapies Affect Risk of Pancreatic Cancer
Li, D., Yeung, S. J., Hassan, M. M., Konopleva, M., & Abbruzzese, J. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.013 · Cited by 584 · cited 2×
“Supporting the idea of these direct effects, metformin reportedly potentiated the effect of neoadjuvant chemotherapy in early-stage breast cancer [87], decreased the risk of colorectal cancer in a small randomized trial involving non-diabetic subjects [88], and was associated with a decreased cancer risk while another…”
BackgroundThe insulin signalling system and the IRS proteins
White, M. F. (1997) · Diabetologia · doi:10.1007/s001250051387 · Cited by 581
Diabetes mellitus and risk of endometrial cancer: a meta-analysis
Friberg, E., Orsini, N., Mantzoros, C. S., & Wolk, A. (2007) · Diabetologia · doi:10.1007/s00125-007-0681-5 · Cited by 562
Randomized Trials or Observational Tribulations?
Pocock, S. J., & Elbourne, D. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422511 · Cited by 550 · cited 1×
“causality because of possible biases and confounders, such as coexisting obesity and age [15,80,81].”
BackgroundMetabolic syndrome, hyperinsulinemia, and colon cancer: a review
Giovannucci, E. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.836s · Cited by 531
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
A meta-analysis of diabetes mellitus and the risk of prostate cancer
Kasper, J. S., & Giovannucci, E. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0410 · Cited by 491 · cited 1×
“prostate cancer [8,9], since it is testosterone-dependent and”
BackgroundLow testosterone levels are common and associated with insulin resistance in men with diabetes
Grossmann, M., Thomas, M. C., Panagiotopoulos, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., & Jerums, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2177 · Cited by 468
Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2010) · Diabetes Care · doi:10.2337/dc09-1791 · Cited by 466
Prospective Study of Adult Onset Diabetes Mellitus (Type 2) and Risk of Colorectal Cancer in Women
Hu, F. B., Manson, J. E., Liu, S., Hunter, D., Colditz, G. A., Michels, K. B., Speizer, F. E., & Giovannucci, E. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.542 · Cited by 423
Diabetes mellitus and breast cancer
Wolf, I., Sadetzki, S., Catane, R., Karasik, A., & Kaufman, B. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)01736-5 · Cited by 422
Abnormal Glucose Metabolism and Pancreatic Cancer Mortality
Gapstur, S. M. (2000) · JAMA · doi:10.1001/jama.283.19.2552 · Cited by 420
Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
Memmott, R. M., Mercado, J. R., Maier, C. R., Kawabata, S., Fox, S. D., & Dennis, P. A. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0055 · Cited by 408 · cited 1×
“An animal study suggested that metformin prevented smokingrelated lung cancer in mice, probably by inducing some hormone from the liver [97].”
BackgroundSilverman, D. T., Schiffman, M., Everhart, J., Goldstein, A., Lillemoe, K. D., Swanson, G. M., Schwartz, A. G., Brown, L. M., Greenberg, R. S., Schoenberg, J. B., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690607 · Cited by 397
Metformin: Taking away the candy for cancer?
Jalving, M., Gietema, J. A., Lefrandt, J. D., Jong, S. D., Reyners, A. K. L., Gans, R. O. B., & Vries, E. G. E. D. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.06.012 · Cited by 380 · cited 2×
“The fact that one preliminary study suggested a promising effect of metformin on pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer [87] may point to the possibility that metformin simply augmented the efficacy of chemotherapy for breast cancer [18,86].”
BackgroundLee, M.-S., Hsu, C.-C., Wahlqvist, M. L., Tsai, H.-N., Chang, Y.-H., & Huang, Y.-C. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-20 · Cited by 380
Insulin resistance and breast‐cancer risk
Bruning, P. F., Bonfrèr, J. M. G., van Noord, P. A. H., Hart, A. A. M., de Jong‐Bakker, M., & Nooijen, W. J. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520402 · Cited by 361
Nutrition, hormones, and breast cancer: Is insulin the missing link?
Kaaks, R. (1996) · Cancer Causes and Control · doi:10.1007/bf00051703 · Cited by 360
Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence
Xue, F., & Michels, K. B. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.823s · Cited by 353
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients
Yang, Y., Hennessy, S., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.011 · Cited by 350 · cited 2×
“The effect on the total cancer risk over the follow-up period was inspected in 3 studies [40,55,58].”
BackgroundDiabetes mellitus and risk of prostate cancer: a meta-analysis
Bonovas, S., Filioussi, K., & Tsantes, A. (2004) · Diabetologia · doi:10.1007/s00125-004-1415-6 · Cited by 327 · cited 1×
“prostate cancer [8,9], since it is testosterone-dependent and”
BackgroundPrevention of pancreatic cancer induction in hamsters by metformin
Schneider, M. B., Matsuzaki, H., Haorah, J., Ulrich, A., Standop, J., Ding, X., Adrian, T. E., & Pour, P. M. (2001) · Gastroenterology · doi:10.1053/gast.2001.23258 · Cited by 327 · cited 1×
“For instance, elevated levels of insulin and glucose may exert an important influence in the development or growth of epithelial malignant tumors of the colon [91–93], pancreas [94,95], and breast [96], and metformin may prevent incident colon cancer in non-diabetic subjects [88].”
BackgroundInsulin-like Growth Factors and Cancer
LeRoith, D., Baserga, R., Helman, L., & Roberts Jr., C. T. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00009 · Cited by 317
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
Hassan, M. M., Curley, S. A., Li, D., Kaseb, A., Davila, M., Abdalla, E. K., Javle, M., Moghazy, D. M., Lozano, R. D., Abbruzzese, J. L., et al. (2010) · Cancer · doi:10.1002/cncr.24982 · Cited by 309 · cited 1×
“Among the studies evaluating the risks of site-specific incident cancers in patients with diabetes who were taking metformin, more than two studies (including subgroup analyses) recognized significantly reduced risks for cancers of the pancreas [36,39,54], colorectum [36,39,40], and liver [29,39,53], and none showed a…”
BackgroundDiabetes mellitus and risk of bladder cancer: a meta-analysis
Larsson, S. C., Orsini, N., Brismar, K., & Wolk, A. (2006) · Diabetologia · doi:10.1007/s00125-006-0468-0 · Cited by 304
Zakikhani, M., Dowling, R. J. O., Sonenberg, N., & Pollak, M. N. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0081 · Cited by 294
Donadon, V., Balbi, M., Mas, M. D., Casarin, P., & Zanette, G. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02223.x · Cited by 292 · cited 1×
“Among the studies evaluating the risks of site-specific incident cancers in patients with diabetes who were taking metformin, more than two studies (including subgroup analyses) recognized significantly reduced risks for cancers of the pancreas [36,39,54], colorectum [36,39,40], and liver [29,39,53], and none showed a…”
BackgroundReduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes
Zhang, Z.-J., Zheng, Z.-J., Kan, H., Song, Y., Cui, W., Zhao, G., & Kip, K. E. (2011) · Diabetes Care · doi:10.2337/dc11-0512 · Cited by 291 · cited 2×
“Compared with recently published studies [18,19], our updated”
BackgroundResultTherapy Insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer
Richardson, L. C., & Pollack, L. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0062 · Cited by 289 · cited 1×
“genesis directly [71,72] or indirectly by increasing oxidative stress [73–79].”
BackgroundWright, J. L., & Stanford, J. L. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9407-y · Cited by 276
Stocks, T., Rapp, K., Bjørge, T., Manjer, J., Ulmer, H., Selmer, R., Lukanova, A., Johansen, D., Concin, H., Tretli, S., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000201 · Cited by 243
Piccinni, C., Motola, D., Marchesini, G., & Poluzzi, E. (2011) · Diabetes Care · doi:10.2337/dc10-2412 · Cited by 239 · cited 1×
“Supporting the idea of these direct effects, metformin reportedly potentiated the effect of neoadjuvant chemotherapy in early-stage breast cancer [87], decreased the risk of colorectal cancer in a small randomized trial involving non-diabetic subjects [88], and was associated with a decreased cancer risk while another…”
BackgroundAlgire, C., Amrein, L., Zakikhani, M., Panasci, L., & Pollak, M. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0252 · Cited by 234
Sulphonylureas and cancer: a case-control study
Monami, M., Lamanna, C., Balzi, D., Marchionni, N., & Mannucci, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0083-2 · Cited by 194 · cited 3×
“studies [55,56]) reported a significant decrease (range, 26%–88%), the two RCTs showed no significant effect of association [46–48]”
BackgroundPostoperative Mortality in Cancer Patients With Preexisting Diabetes
Barone, B. B., Yeh, H.-C., Snyder, C. F., Peairs, K. S., Stein, K. B., Derr, R. L., Wolff, A. C., & Brancati, F. L. (2010) · Diabetes Care · doi:10.2337/dc09-1721 · Cited by 185 · cited 1×
“In light of the worldwide diabetes epidemic and the higher mortalities in cancer patients with diabetes [20,21], explorations of effective cancer prevention are of clinical importance for the targeted management of diabetes in daily practice.”
Backgroundfor the ADOPT Study Group and the RECORD Steering Committee, Home, P. D., Kahn, S. E., Jones, N. P., Noronha, D., Beck-Nielsen, H., & Viberti, G. (2010) · Diabetologia · doi:10.1007/s00125-010-1804-y · Cited by 177
Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Uchiyama, T., Suzuki, K., Nozaki, Y., Yoneda, K., Fujita, K., Yoneda, M., et al. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20637 · Cited by 177 · cited 2×
“Supporting the idea of these direct effects, metformin reportedly potentiated the effect of neoadjuvant chemotherapy in early-stage breast cancer [87], decreased the risk of colorectal cancer in a small randomized trial involving non-diabetic subjects [88], and was associated with a decreased cancer risk while another…”
BackgroundAGE-RAGE System and Carcinogenesis
Abe, R., & Yamagishi, S.-I. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784139765 · Cited by 169
Noto, H., Tsujimoto, T., Sasazuki, T., & Noda, M. (2011) · Endocrine Practice · doi:10.4158/ep10357.ra · Cited by 168 · cited 1×
“These circumstances prompted us to investigate, with greater precision, the preventive effect of metformin on cancer mortality and incidence by scrutinizing pertinent original reports including randomized controlled trials (RCTs), and combining their data in an attempt to obtain meaningful clues for the prevention of…”
BackgroundSelf-citationImpact of Metformin on the Prognosis of Cirrhosis Induced by Viral Hepatitis C in Diabetic Patients
Nkontchou, G., Cosson, E., Aout, M., Mahmoudi, A., Bourcier, V., Charif, I., Ganne-Carrie, N., Grando-Lemaire, V., Vicaut, E., Trinchet, J.-C., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2415 · Cited by 166 · cited 1×
“Four articles [27–30] were excluded from the systematic review because of population overlapping and four other reports were excluded because they investigated the overall survival rate [31,32], cancer incidence exclusively in patients with hepatitis C [33], and biochemical recurrence [34].”
BackgroundBowker, S. L., Yasui, Y., Veugelers, P., & Johnson, J. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1750-8 · Cited by 165
He, X., Tu, S., Lee, M., & Yeung, S. J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr020 · Cited by 161 · cited 1×
“Four articles [27–30] were excluded from the systematic review because of population overlapping and four other reports were excluded because they investigated the overall survival rate [31,32], cancer incidence exclusively in patients with hepatitis C [33], and biochemical recurrence [34].”
BackgroundBosco, J. L. F., Antonsen, S., Sørensen, H. T., Pedersen, L., & Lash, T. L. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0817 · Cited by 147
Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease
Donadon, V., Balbi, M., Ghersetti, M., Grazioli, S., Perciaccante, A., Valentina, G. D., Gardenal, R., Mas, M. D., Casarin, P., Zanette, G., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2506 · Cited by 145
Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan
Tseng, C. (2011) · Diabetologia · doi:10.1007/s00125-011-2171-z · Cited by 142
Diabetes and Risk of Non-Hodgkin's Lymphoma
Mitri, J., Castillo, J., & Pittas, A. G. (2008) · Diabetes Care · doi:10.2337/dc08-1034 · Cited by 140
Substantially increased risk of cancer in patients with diabetes mellitus
Noto, H., Osame, K., Sasazuki, T., & Noda, M. (2010) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2010.06.004 · Cited by 136 · cited 1×
“The anti-cancer effect of metformin may also be applicable to diabetic Asians, who are generally lean and insulinopenic [12], given the fact that they have a higher cancer risk than nondiabetic Asians [12–14] and the data for Asians [39] were in line with the results of our meta-analyses.”
ResultSelf-citationMetformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes
Azoulay, L., Dell'Aniello, S., Gagnon, B., Pollak, M., & Suissa, S. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0940 · Cited by 133
Diabetes Mellitus and Risk of Colorectal Cancer in the Singapore Chinese Health Study
Seow, A., Yuan, J.-M., Koh, W.-P., Lee, H.-P., & Yu, M. C. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj015 · Cited by 129
van Staa, T. P., Patel, D., Gallagher, A. M., & Bruin, M. L. D. (2011) · Diabetologia · doi:10.1007/s00125-011-2390-3 · Cited by 128 · cited 4×
“early cancer leading to unstable diabetes and hyperglycemia, with patients switching diabetes treatment) [15] may remain moderate.”
BackgroundInfluentialDiabetes and Risk of Prostate Cancer
Tseng, C.-H. (2011) · Diabetes Care · doi:10.2337/dc10-1640 · Cited by 123
for the DIGAMI 2 Investigators, Mellbin, L., Malmberg, K., Norhammar, A., Wedel, H., & Rydén, L. (2011) · Diabetologia · doi:10.1007/s00125-011-2084-x · Cited by 114 · cited 1×
“All the four cohort studies [35,38,40,41] on cancer mortality revealed a significant decrease (range, 23%– 75%), and the two RCTs showed no significant effect of metformin [49].”
BackgroundMetformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
Monami, M., Colombi, C., Balzi, D., Dicembrini, I., Giannini, S., Melani, C., Vitale, V., Romano, D., Barchielli, A., Marchionni, N., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1287 · Cited by 109 · cited 2×
“studies [55,56]) reported a significant decrease (range, 26%–88%), the two RCTs showed no significant effect of association [46–48]”
BackgroundChen, T., Lin, C., Huang, P., & Wen, C. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06664.x · Cited by 107 · cited 1×
“Four articles [27–30] were excluded from the systematic review because of population overlapping and four other reports were excluded because they investigated the overall survival rate [31,32], cancer incidence exclusively in patients with hepatitis C [33], and biochemical recurrence [34].”
BackgroundFurther Exploration of the Relationship Between Insulin Glargine and Incident Cancer
Morden, N. E., Liu, S. K., Smith, J., Mackenzie, T. A., Skinner, J., & Korc, M. (2011) · Diabetes Care · doi:10.2337/dc11-0699 · Cited by 94 · cited 1×
“Of note, no significant increases or decreases in the risk of cancers of the breast, prostate or stomach were reported, except for a significant decrease in the risk of prostate cancer in one report [42] and breast”
BackgroundClinical Outcomes After Radical Prostatectomy in Diabetic Patients Treated With Metformin
Patel, T., Hruby, G. W., Badani, K. K., Abate-Shen, C. T., & McKiernan, J. M. (2010) · Urology · doi:10.1016/j.urology.2010.03.059 · Cited by 90 · cited 2×
“In fact, one cohort study reported no benefit of metformin in terms of the biochemical recurrence rate after radical prostatectomy in diabetic patients [34].”
BackgroundUse of sulphonylurea and cancer in type 2 diabetes—The Hong Kong Diabetes Registry
Yang, X., So, W. Y., Ronald, C. W., Yu, L. W., Ko, G. T. C., Kong, A. P. S., Ng, V., Luk, A. O. Y., Ozaki, R., Tong, P. C. Y., et al. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.08.022 · Cited by 89
Wotton, C. J., Yeates, D., & Goldacre, M. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1987-2 · Cited by 87 · cited 2×
“7) [12–14], whereas more recent studies did not [15,16].”
BackgroundClyne, A. M., & Edelman, E. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608565200 · Cited by 81 · cited 1×
“genesis directly [71,72] or indirectly by increasing oxidative stress [73–79].”
BackgroundDiet, Lifestyle, and Colorectal Cancer: Is Hyperinsulinemia the Missing Link?
Kim, Y.-I. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1998.tb01765.x · Cited by 74
Low HDL Cholesterol, Metformin Use, and Cancer Risk in Type 2 Diabetes
Yang, X., So, W. Y., Ma, R. C. W., Kong, A. P. S., Lee, H. M., Yu, L. W. L., Chow, C.-C., Ozaki, R., Ko, G. T. C., & Chan, J. C. N. (2011) · Diabetes Care · doi:10.2337/dc10-1509 · Cited by 68
Noto, H., Tsujimoto, T., & Noda, M. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00183.x · Cited by 65
Self-citationJohnson, J. A., & Gale, E. A. M. (2010) · Diabetes · doi:10.2337/db10-0334 · Cited by 64
Insulin-like Growth Factors and Cancer
Yu, H., & Berkel, H. J. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0598-6 · Cited by 55
Inoue, M., Kurahashi, N., Iwasaki, M., Tanaka, Y., Mizokami, M., Noda, M., & Tsugane, S. (2008) · Cancer Causes & Control · doi:10.1007/s10552-008-9287-6 · Cited by 55
Self-citationType 2 Diabetes Mellitus and Risk of Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
Chao, C., & Page, J. H. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn160 · Cited by 55
Diabetes Mellitus and Increased Risk of Cancer: Focus on Metformin and the Insulin Analogs
McFarland, M. S., & Cripps, R. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.11.1159 · Cited by 53 · cited 2×
“the data from insulin-treated patients are inconclusive [82].”
BackgroundHense, H.-W., Kajüter, H., Wellmann, J., & Batzler, W. U. (2011) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-3-15 · Cited by 40
Zhang, W., Thornton, W. H., & MacDonald, R. S. (1998) · Journal of Nutrition · doi:10.1093/jn/128.2.158 · Cited by 32
Do Diabetes Drugs Modify the Risk of Pancreatic Cancer?
Yang, Y. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.022 · Cited by 30
Cited by
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
ROS signalling in the biology of cancer
Moloney, J. N., & Cotter, T. G. (2018) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.05.023 · Cited by 1,970
The hallmarks of cancer metabolism: still emerging
Pavlova, N. N., Zhu, J., & Thompson, C. B. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.01.007 · Cited by 1,418
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
“Furthermore, retrospective clinical studies have found that metformin use is associated with improved cancer outcomes, reductions in cancer incidence, and decreased cancer mortality (Evans et al., 2005; Franciosi et al., 2013; Gandini et al., 2014; Lee et al., 2012; Noto et al., 2012).”
BackgroundMitochondrial reactive oxygen species and cancer
Sullivan, L. B., & Chandel, N. S. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-17 · Cited by 786
“drug metformin have recently been shown to have a reduced risk of cancer incidence and mortality [101].”
Background
Metadata
- Authors
- Noto, H., Goto, A., Tsujimoto, T., & Noda, M.
- Affiliations
- National Center for Global Health and Medicine (JP)
- Corresponding author
- Noto, Hiroshi
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-20
- Volume
- 7
- Issue
- 3
- Pages
- e33411
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3308971
- OpenAlex
- W2040608814
- Cited by
- 566
- References
- 106
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 20 · 2023: 29 · 2022: 28 · 2021: 33 · 2020: 41 · 2019: 38 · 2018: 28 · 2017: 50 · 2016: 60 · 2015: 57 · 2014: 60 · 2013: 65 · 2012: 25
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Health, Labour and Welfare
- Japan Diabetes Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metformin, diabetes mellitus, cancer risk, cancer mortality, cancer incidence, colorectal cancer, hepatocellular carcinoma, lung cancer, chemoprevention
- MeSH terms
- Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Risk Factors, Meta-Analysis as Topic, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.